NCT04123613已完成2 期
A Multi-Center Open-label Investigation to Assess the Safety and Efficacy of Multiple Doses of DM199 in Patients With Chronic Kidney Disease
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 入组人数
- 79
- 试验地点
- 14
- 主要终点
- Plasma measurements of DM199
研究概览
简要总结
An open-label, Phase II, multi-center study evaluating multiple doses of DM199 in participants with chronic kidney disease.
详细描述
This is an open-label, Phase II, multi-center study evaluating DM199 in approximately 90 Participants in three cohorts.
Cohort I: African Americans with CKD (Stage II or III), hypertension and non-diabetic Cohort II: Participants with IgA nephropathy diagnosis and CKD (Stage II or III) Cohort III: Diabetes Mellitus (Type II) with CKD (Stage II or III) and hypertension
Participants in each cohort will be enrolled in a parallel assignment to one of two doses:
Dose 1: DM199 2.0 µg/kg SC 2x week for 95 days Dose 2: DM199 5.0 µg/kg SC 2x week for 95 days
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •African American
- •Hypertension as defined by the American Heart Association for Stage I hypertension where systolic blood pressure (BP) ≥130 mmHg or diastolic BP ≥ 80 mmHg or on medication for treatment of hypertension.
- •IgA nephropathy confirmed by medical history with biopsy
- •Diabetes Mellitus (Type 2) with hypertension where systolic blood pressure (BP) ≥130 mmHg or diastolic BP ≥ 80 mmHg or on medication for treatment of hypertension
- •Hemoglobin A1c ≥7% at screening
- •Both Cohorts
- •Participant is willing and able to provide informed consent for study participation
- •Participant male or female ≥ 18 years of age
- •Participant has CKD as defined by using CKD EPI for Stage II 60 to <90 mL/min/1.73 m2 or Stage III 30 to <60 mL/min/1.73 m2
- •UACR >150 mg/g and <5000 mg/g at screening
- •Participant is clinically stable with respect to underlying renal impairment as assessed by the Investigator's medical evaluation
排除标准
- •Participant has positive drug test for drugs of abuse and/or positive alcohol breath test at screening and Day 1
- •Participant has a current diagnosis and/or is taking medication or diet control for diabetes (cohort I and II only)
- •Participant has an A1c > 7% at screening (cohort I and II only)
- •Participant received corticosteroid therapy within last 3 months
- •Participant is unable or unwilling to comply with protocol requirements, including assessments, tests, and follow-up visits
- •Participant has a history of significant allergic diathesis such as urticaria, angioedema, or anaphylaxis
- •Participant has been previously diagnosed with kidney disease other than for hypertension, IgA or Diabetes Mellitus (Type II)
- •Participant has hypotension as defined by systolic blood pressure ≤ 90 mmHg and diastolic blood pressure ≤ 60 mmHg at screen
- •ACEi or GLP-1 medication prescribed for and taken by Participant (must not be taking for 5 half-lives prior to study drug administration and for 10 days post study drug administration)
- •Participant has a current malignancy or active malignancy ≤ 2 years prior to enrollment except basal cell or squamous cell carcinoma of the skin or in situ cervical cancer that has undergone potentially curative therapy and ≥ 6 months have elapsed since the procedure
- •Participant has an active infection at the time of enrollment, and/or a history of clinically significant acute bacterial, viral, or fungal systemic infections that required systemic treatment with a completed therapy in the last 7 days prior to enrollment
- •Participant has known medical history of alpha 1-antitrypsin deficiency (α1-antitrypsin deficiency)
- •Participant is pregnant or nursing or is planning a pregnancy during the study period
- •Participant is male or female of childbearing potential, is participating in sexual activity that could lead to pregnancy and is unable or unwilling to practice medically effective contraception during the study
- •Participant has received any investigational drug or device within 14 days (or 5 half lives, whichever is longer) prior to study drug administration starting on Day 1
- •Participant has renal artery stenosis as determined at screen with medical history
- •Participant received a kidney transplant
- •Participant does not have adequate venous access for blood sampling
- •Participant has any other medical condition which, in the opinion of the Investigator, will make participation medically unsafe or interfere with the study results
- •Participant has any other clinically significant abnormalities in laboratory test results at screening that would, in the opinion of the Investigator, increase the Participant's risk of participation, jeopardize complete participation in the study, or compromise interpretation of study data
- •Participant has any significant arrhythmia or conduction abnormality, which in the opinion of the Investigators and Medical Monitor may interfere with the safety of the Participant
研究组 & 干预措施
2.0 µg/kg, multiple dose
Experimental
n=45 with 15 Participants from cohort 1, 15 from cohort 2, and 15 from cohort 3
干预措施: DM199 (Drug)
5.0 µg/kg, multiple dose
Experimental
n=45 with 15 Participants from cohort 1, 15 from cohort 2 and 15 from cohort 3
干预措施: DM199 (Drug)
结局指标
主要结局
Plasma measurements of DM199
时间窗: 12 weeks
Maximum plasma concentration of DM199
Incidence of treatment emergent adverse events
时间窗: 12 weeks
Incidence, severity, and causality of adverse events
Change in renal function
时间窗: 12 weeks
eGFR
Change in urine albumin to creatinine ratio
时间窗: 12 weeks
UACR change from baseline
次要结局
- Tumor necrosis factor receptor 1 (TNF R1) concentration in plasma, change from baseline(12 weeks)
- C-reactive protein (CRP) concentration in plasma, change from baseline(12 weeks)
- Vascular endothelial growth factor (VEGF) concentration in plasma, change from baseline(12 weeks)
- Cystatin C concentration in plasma, change from baseline(12 weeks)
- Matrix metalloproteainase-9 (MMP-9) concentration in plasma, change from baseline(12 weeks)
- Prostaglandin E2 concentration in plasma, change from baseline(12 weeks)
- Prostacyclin concentration in plasma, change from baseline(12 weeks)
研究者
研究点 (14)
Loading locations...
相似试验
已完成
1 期
Study to Assess PK, Safety and Tolerability in Patients With DM and CKDChronic Kidney Disease, Stage 3 (Moderate)Chronic Kidney Disease, Stage 4 (Severe)DiabetesChronic Kidney DiseaseNCT03795389DiaMedica Therapeutics Inc33
已完成
2 期
The ELiSA Study - Evaluation of Lixivaptan in Subjects With Autosomal Dominant Polycystic Kidney DiseaseAutosomal Dominant Polycystic Kidney DiseaseNCT03487913Palladio Biosciences31
撤回
2 期
Study of Imdusiran (AB-729) in Combination With Intermittent Dosing of Durvalumab in Subjects With Chronic HBV InfectionHepatitis B, ChronicNCT06245291Arbutus Biopharma Corporation
撤回
2 期
A Phase 2, Multicenter, Open-label Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Pefcalcitol Ointment, 0.005%, Applied Topically Twice Daily (BID) for 8 Weeks in Adolescent Subjects 12 to < 17 Years of Age With Plaque PsoriasisPsoriasisNCT02970331Maruho Co., Ltd.
尚未招募
1 期
A Study of Docetaxel for Injection (Albumin-bound) and SG001 in Combination With Cisplatin and Simultaneous Radiotherapy for Locally Advanced Unresectable Esophageal Squamous Carcinoma.Locally Advanced Unresectable Esophageal Squamous CarcinomaNCT06136988CSPC ZhongQi Pharmaceutical Technology Co., Ltd.129